Novo Nordisk A/S (NVO): Price and Financial Metrics
Novo Nordisk A/S (NVO)
Today's Latest Price: $72.03 USD
Updated Jan 15 7:00pm
Add NVO to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 239 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
NVO Stock Summary
- NVO has a higher market value than 98.85% of US stocks; more precisely, its current market capitalization is $167,481,637,000.
- Novo Nordisk A S's stock had its IPO on January 1, 1986, making it an older stock than 92.8% of US equities in our set.
- In terms of volatility of its share price, NVO is more volatile than just 0.8% of stocks we're observing.
- Stocks with similar financial metrics, market capitalization, and price volatility to Novo Nordisk A S are MDT, DHR, SAP, TXN, and LLY.
- NVO's SEC filings can be seen here. And to visit Novo Nordisk A S's official web site, go to www.novonordisk.com.
NVO Stock Price Chart Interactive Chart >
NVO Price/Volume Stats
| Current price | $72.03 | 52-week high | $73.92 |
| Prev. close | $71.03 | 52-week low | $49.24 |
| Day low | $71.39 | Volume | 1,011,600 |
| Day high | $72.29 | Avg. volume | 1,074,580 |
| 50-day MA | $69.21 | Dividend yield | 1.03% |
| 200-day MA | $66.78 | Market Cap | 169.62B |
Novo Nordisk A/S (NVO) Company Bio
Novo Nordisk A/S engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Biopharmaceuticals. The company was founded in 1925 and is based in Bagsvaerd, Denmark.
NVO Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $72.03 | $127.23 | 77% |
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Novo Nordisk A S. To summarize, we found that Novo Nordisk A S ranked in the 65th percentile in terms of potential gain offered. Moreover, under all the scenarios we modelled, the output consistently forecasted positive returns. In terms of the factors that were most noteworthy in this DCF analysis for NVO, they are:
- In the past 4.74 years, Novo Nordisk A S has a compound free cash flow growth rate of 0.03%; that's higher than only 23.4% of free cash flow generating stocks in the Healthcare sector.
- The business' balance sheet suggests that 0% of the company's capital is sourced from debt; this is greater than just 3.84% of the free cash flow producing stocks we're observing.
- NVO's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 3%; for context, that number is higher than 57.11% of tickers in our DCF set.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | 73% |
| 1% | 75% |
| 2% | 77% |
| 3% | 78% |
| 4% | 80% |
| 5% | 82% |
Want more companies with a valuation profile/forecast similar to that of Novo Nordisk A S? See FMS, DVA, FZMD, PNTG, and DGX.
Loading social stream, please wait...